Piramal Pharma Solutions unveils state-of-the-art payload-linker suite in US

Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma (PPS), has officially unveiled a new, state-of-the-art payload-linker development and manufacturing suite at its Riverview, Michigan drug substance facility.

This launch is a key element of the company's broader $90 million investment plan to extend US-based manufacturing capabilities, announced last year. In addition to the payload-linker suite, the plan will add new technology and enhanced commercial-scale manufacturing capabilities at PPS's dedicated sterile injectables facility in Lexington, Kentucky.

With over 60 years of drug substance development and manufacturing experience, Riverview is a distinguished leader in its field. Drawing on its diverse expertise, the site provides a comprehensive range of capabilities for APIs and HPAPIs. Leveraging its specialised Highly Potent Active Pharmaceutical Ingredient (HPAPI) knowledge and abilities, Riverview serves as PPS's dedicated payload-linker supplier, making it critical to ADCelerate™ – PPS's rapid, integrated approach to phase I antibody drug conjugate (ADC) development.

The addition of this payload-linker suite is designed to help PPS accelerate partners' timelines and adapt to evolving market needs. Equipped with advanced containment, automation, and analytical technologies, the suite enables seamless scaling of payload-linker programmes. This further strengthens the ADCelerate™ platform and positions PPS to meet the rising demand for ADCs and other bioconjugate therapies.